E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

Health Market Industry
More Pages: Page: (1) 2 3 4 5 6 7 8 9 10 11 ... 40
NYSE:AVN12% APPLE INC. CALLABLE STRIDES DUE SEPTEMBER 04,
 Avanir Pharmaceuticals is engaged as a drug discovery and development company focused on treatments for chronic diseases. Co.'s lead product candidate, Neurodex , has completed Phase III clinical trial fors pseudobulbar affect in patients with multiple sclerosis and in patients with Lou Gehrig's disease, also known as emotional lability, and a Phase II clinical trial for diabetic neuropathic pain. Co. also has a potential product for allergy and asthma, AVP-13358, which is in Phase I clinical development. Co.'s first commercialized product is Abreva . Abreva is an over-the-counter product for the treatment of cold sores.
 Market CapDay's VolumeLast TradeChange
 -0$27.82010.0%
 
NASDAQ:SSRX3SBIO SP ADR
 3SBio is principally engaged in the research, development, manufacture and distribution of pharmaceutical products in the People's Republic of China ("PRC"). Co. manufactures four types of biopharmaceutical products, making use of technical know-how injected by the former majority shareholder of Shenyang Sunshine Pharmaceutical Company Limited and Co.'s own research and development. Co.'s major products are EPIAO, TPIAO, and its two legacy products including Intefen and Inleusin. Co. operates and manages its business solely in the PRC and sales are predominantly made to customers located in the PRC.
 Market CapDay's VolumeLast TradeChange
 -48,929$14.95+0.0669%
 
OTC PK:FDNU4-D Neuroimaging
 4-D Neuroimaging develops, produces, markets and sells medical instrumentation that allows physicians to monitor how the body is functioning under a basic technology referred to as Magnetoencephalography ("MEG"). MEG systems measure and locate magnetic fields generated by the human body, and assist in the noninvasive diagnosis of a range of medical disorders. These measurements provide useful information about the normal and abnormal functioning of the brain, heart, spine and other organs. MEG systems are used to measure the magnetic fields, from the brain or body thousands of times a second for the surgical treatment of epilepsy and the identification of functional areas of the brain.
 Market CapDay's VolumeLast TradeChange
 $19M0$0.020.0%
 
NASDAQ:ASTMAASTROM BIOSCIENCES
 Aastrom Biosciences is engaged as a regenerative medicine company (a medical area that focuses on developing therapies that regenerate damaged or diseased tissues or organs) focused on the clinical development of autologous cell products (cells collected from a patient and returned to that same patient) for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell (TRC) Technology. Co.'s preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations, and are being investigated for their ability to aid in the regeneration of tissues such as bone, vascular, cardiac and neural.
 Market CapDay's VolumeLast TradeChange
 $60M108,990$1.54+0.6535%
 
NASDAQ:ABAXABAXIS
 Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with blood constituent measurements. Co. markets its products to two customer groups: medical market and veterinary. Co. markets the system in the medical market under the name Piccolo xpress , and in the veterinary market the system is marketed under the name VetScan VS2 and VetScan Classic. Co.'s other products and technology include Reagent Discs, Hematology instrument and the Orbos Discrete Lyophilization Process . Co. markets and sells its products worldwide by maintaining direct sales forces and through independent distributors.
 Market CapDay's VolumeLast TradeChange
 -132,174$20.96-1.0388%
 
NYSE:ABTAbbott Laboratories
 Abbott Laboratories is principally engaged in the discovery, development, manufacture and sale of a variety of health care products through four business segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Co.'s primary products are prescription pharmaceuticals, nutritional products, vascular products and diagnostic testing products. In addition, Co. has a 50.0%-owned joint-venture, TAP Pharmaceutical Products Inc. with Takeda Pharmaceutical Company Ltd. of Japan, through which Co. develops, markets and sells pharmaceutical products such as Lupron , Lupron Depot and Prevacid (lansoprazole), within the U.S., Puerto Rico and Canada.
 Market CapDay's VolumeLast TradeChange
 $78,871M5,896,717$49.98-0.3986%
 
NASDAQ:ABMDABIOMED INC
 ABIOMED is a developer, manufacturer and marketer of medical products and services in the area of circulatory care. The products Co. designs for heart recovery are AB5000 and BVS 5000. The BVS and AB5000 systems each consist of single-use external blood pumps and cannulae and a reusable pneumatic drive and control console. Co. introduced an IAB designed to enhance blood flow to the heart and other organs, Co.'s AbioCor is a battery-powered implantable replacement heart system. Co. manufactures its products in Danvers, MA and Aachen, Germany. Co.'s U.S. operations manufacture the BVS, AB5000, AbioCor and other products. Co.'s Aachen facility manufactures all of its Impella products.
 Market CapDay's VolumeLast TradeChange
 -356,084$10.26-2.2858%
 
NASDAQ:ACADACADIA PHARMA
 Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. As of Dec 31 2006, Co. had five programs in clinical development and several additional programs in preclinical development and discovery stages. Also, Co is entering Phase III development with ACP-103 for the treatment of Parkinson's disease psychosis. Further, Co.'s three proprietary Phase II-stage clinical programs, including ACP-103 as a co-therapy for schizophrenia, ACP-103 for the treatment of sleep maintenance insomnia, and ACP-104 for the treatment of schizophrenia.
 Market CapDay's VolumeLast TradeChange
 -592,207$1.15-3.3614%
 
OTC PK:ACAMFAcambis plc
 Acambis is engaged in the research, development and manufacture of vaccines to prevent and treat infectious diseases.
 Market CapDay's VolumeLast TradeChange
 $244M0$3.400.0%
 
NYSE:ALOACCELERATED RETURN NOTES LINKED TO S&P500 INDEX
 Alpharma is a global specialty pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products for humans and animals. Co. markets one branded pharmaceutical prescription product, a pain medication sold under the trademark KADIAN . Co. also manufactures and markets a line of fermentation-based active pharmaceutical ingredients that are used in the manufacturing of generic and branded pharmaceutical products. As of Dec 31 2006, Co. manufactured and marketed 100 animal health products and conducted business in more than 80 countries. Additionally, Co. operates through three segments:Pharmaceuticals, Active Pharmaceutical Ingredients and Animal Health.
 Market CapDay's VolumeLast TradeChange
 -600$10.11+0.7976%
 
NASDAQ:ACCLACCELRYS
 Accelrys is engaged in the design, development, marketing, and support of software based applications for the aggregation, mining, integration, analysis, simulation, management and reporting of scientific data used by biologists, chemists, materials scientists including nanotechnology researchers, and information technology professionals for product design and drug discovery and development. Co. markets its products and services worldwide, principally through its direct sales force and third-party distributors. At Mar 31 2007, Co.'s product line included Scientific Operating Platform, Modeling and Simulation Software, and Informatics Software.
 Market CapDay's VolumeLast TradeChange
 -120,601$6.87-1.0087%
 
OTC PK:ABPIAccentia Biopharmaceuticals, Inc.
 Accentia Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. Co. has two product candidates with fast-track status in Phase 3 clinical trials. Co.'s first product candidate, SinuNase?, has been developed as a treatment for chronic rhinosinusitis, also commonly referred to as chronic sinusitis. Co.'s second product candidate, BiovaxID?, is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma.
 Market CapDay's VolumeLast TradeChange
 $106M0$0.230.0%
 
OTCBB:ACCPAccess Pharmaceuticals, Inc.
 Access Pharmaceuticals is a biopharmaceutical company developing products for use in the treatment of cancer, the supportive care of cancer, and other disease states. As of Dec 31 2006, Co.'s key clinical development program for its drug candidate ProLindac? is in Phase II clinical testing. In addition, Co. is developing other drug delivery technologies including Cobalamin ?-mediated oral drug delivery and targeted delivery. Together with its subsidiaries, Co. has proprietary patents or rights to three drug delivery technology platforms, including synthetic polymer targeted delivery, cobalamin-mediated delivery, and mucoadhesive liquid technology.
 Market CapDay's VolumeLast TradeChange
 $7M7,480$2.09-0.4762%
 
NASDAQ:ARAYACCURAY
 Accuray designs, develops and sells the CyberKnife system, an image-guided robotic radiosurgery system used for the treatment of solid tumors anywhere in the body. Co.'s CyberKnife system combines continuous image-guidance technology with a compact linear accelerator that has the ability to move in three dimensions according to the treatment plan. In the U.S., Co. sells its products and services to customers, including hospitals and stand-alone treatment facilities, directly through its sales organization. Outside the U.S., Co. sells to customers in over 45 countries directly and through distributors. Co. also has sales and service offices in Paris, France, Hong Kong, China and Tokyo, Japan.
 Market CapDay's VolumeLast TradeChange
 $529M398,616$6.89+0.7309%
 
NASDAQ:ACHNACHILLION PHARMA
 Achillion Pharmaceuticals is a biopharmaceutical company which discovers, develops and commercializes treatments for infectious diseases. Specifically, Co. concentrates on developing antivirals for human immunodeficiency virus (HIV) infection and chronic hepatitis C treatment and developing antibacterials for serious hospital-based bacterial infections treatment. Co. has advanced its lead drug candidate, elvucitabine for HIV infection treatment, into phase II clinical trials. In addition, it has also advanced two late-stage preclinical candidates, ACH-702 for serious hospital-based bacterial infections treatment and a series of NS4A antagonists for chronic hepatitis C treatment.
 Market CapDay's VolumeLast TradeChange
 -29,353$2.65+1.5325%
 
OTC PK:ACGJACI Global Corporation
 ACI Global is considered to be in a development stage. Co. is in the business of designing and developing proprietary technology to produce synthetic rubber powder and thermoplastic elastomers utilizing its synthetic rubber powder in its chemical composition and to use this technology in the rubber and elastomers manufacturing business.
 Market CapDay's VolumeLast TradeChange
 -0$0.00050.0%
 
NASDAQ:ACORACORDA THERAPEUTICS
 Acorda Therapeutics is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the central nervous system (CNS). Co.'s marketed drug, Zanaflex Capsules , is FDA-approved for the management of spasticity. As of Dec 31 2006, Co.'s product candidate, Fampridine-SR , is in a Phase 3 clinical trial for the improvement of walking ability in people with MS. Co.'s preclinical programs also target MS and SCI as well as other CNS disorders, including stroke and traumatic brain injury.
 Market CapDay's VolumeLast TradeChange
 $535M855,652$35.02-4.7594%
 
OTCBB:AGNMAcrongenomics, Inc.
 Acrongenomics is a development stage company focusing on investing and commercializing technology platforms relating to the life sciences sector. Co. is engaged in the business of the development of BioLED Technology, combining microfluidics and polymer Light Emitting Diodes (pLED) for use in future Point-of-Care diagnostic devices. As of Dec 31 2006, Co. owned patents for EP-CAM Detection Kit? , a proprietary technological product for the detection of epithelial cancer.
 Market CapDay's VolumeLast TradeChange
 -40,900$0.085-9.5745%
 
NASDAQ:ACURACURA PHARMA
 Acura Pharmaceuticals is a pharmaceutical company engaged in research, development and manufacture of Aversion (abuse deterrent) Technology and related product candidates. Aversion Technology is applicable to immediate release and extended release, orally administered tablets and capsules. OxyADF Tablets, Co.'s key product candidate incorporates Aversion Technology with oxycodone HCl as the active analgesic ingredient in an immediate release tablet intended for oral administration. Co. has clearance from the U.S. Food and Drug Administration for testing OxyADF Tablets in a clinical trial program under an active investigational new drug application.
 Market CapDay's VolumeLast TradeChange
 -23,324$2.70-0.7353%
 
OTCBB:ACPHAcura Pharmaceuticals
 Acura Pharmaceuticals is a pharmaceutical company engaged in research, development and manufacture of Aversion (abuse deterrent) Technology and related product candidates. Aversion Technology is applicable to immediate release and extended release, orally administered tablets and capsules. OxyADF Tablets, Co.'s key product candidate incorporates Aversion Technology with oxycodone HCl as the active analgesic ingredient in an immediate release tablet intended for oral administration. Co. has clearance from the U.S. Food and Drug Administration for testing OxyADF Tablets in a clinical trial program under an active investigational new drug application.
 Market CapDay's VolumeLast TradeChange
 $344M0$8.050.0%
 
OTC PK:ACUSAcusphere, Inc.
 Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology. Co. is focused on developing proprietary drugs that can provide benefits over existing drugs, including improved safety and efficacy, increased patient compliance, improved ease of use, expanded indications or reduced cost. Co.'s key product candidate, Imagify (perflubutane polymer microspheres for delivery in an injectable suspension), is a cardiovascular drug in Phase 3 clinical development for the detection of coronary artery disease.
 Market CapDay's VolumeLast TradeChange
 $24M25,026$0.0855+6.875%
 
OTC PK:ACUSPAcusphere, Inc. 6.5% Preferred Conv.
 Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology. Co. is focused on developing proprietary drugs that can provide benefits over existing drugs, including improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost. Co.'s three product candidates for which it has clinical data are designed to address large unmet clinical needs in the areas of cardiology, oncology and asthma. Co.'s primary product candidate is an ultrasound contrast agent in Phase 3 clinical development for the detection of coronary heart disease.
 Market CapDay's VolumeLast TradeChange
 -0$6.380.0%
 
OTC PK:ADGRAdAl Group, Inc.
 AdAl Group manufactures diverse extruded aluminum products, providing services for the architectural, construction, automotive, medical, defense, transportation, and HVAC industries. Co. is engaged in providing manufacturing, fabricating, precision machining, and product design services. Co.'s three operating subsidiaries are Adal Seco, Adal Engineering and Adal Guilform. Seco is a provider of aluminum extrusion design and production services, providing complete supply-chain management. Engineering provides precision engineering, tool making and volume production of machined components for the automotive industry. Adal Guilform is a fabricator of panels for the construction industry.
 Market CapDay's VolumeLast TradeChange
 $0M0$0.00050.0%
 
NYSE:ADKAdCare Health Systems
 AdCare Health Systems is a developer, owner and manager of retirement communities, assisted living facilities, nursing homes and home health care services in Ohio. As of Dec 31 2006, Co. manages 15 facilities, comprised of six skilled nursing centers, seven assisted living residences and two independent living/senior housing facilities, totaling over 800 beds. Co. also maintains a development/consulting initiative which is strategic in providing potential management opportunities to its core long-term care business. Co.'s business operates in two segments: management and facility-based care and home-based care.
 Market CapDay's VolumeLast TradeChange
 -7,550$3.59-0.2778%
 
AMEX:ADHAdherex Technologies, Inc.
 Adherex Technologies is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Co. aim to be a leader in developing innovative treatments that address unmet medical needs in cancer. Co. has multiple products in the clinical stage of development including ADH-1, eniluracil and sodium thiosulfate (STS). ADH-1, Co. biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors.
 Market CapDay's VolumeLast TradeChange
 $44M0$0.03890.0%
 
More Pages: Page: (1) 2 3 4 5 6 7 8 9 10 11 ... 40
More

Investing by Industry or Market Sector employs non-emotional, numbers driven, value-based industry, sector, and country rotation techniques, that, unlike conventional stock picking methods, focuses instead on identifying and capitalizing on theme movements in the well identified industries & market sectors.

Primarily, this active-asset methodology recognizes that advances in financial markets are defined by "themes", or led by asset classes, industries, and countries, with each advance distinguished by specific sector-driven themes. Employing a disciplined research and valuation process these "themes" are identified so that Portfolio's can be created and/or adjusted toward the most attractive sectors.

Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts